PosterSessionOnline

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

NAFLD Summit 2022

15-17 September Dublin

N. Poster

Poster title

Applicant name

Status


P05-001	Impact of resmetirom-mediated reductions in liver volume and steatosis compared with placebo on the quantification of fibrosis using second harmonic generation in a serial liver biopsy study	Stephen Harrison	Received

P03-001	Retrospective artificial intelligence-based measurement of NASH histology (AIM-NASH) analysis of biopsies from phase 2 study of resmetirom confirms significant treatment-induced changes in histologic features of nonalcoholic steatohepatitis	Stephen Harrison	Received

P04-001	Biomarkers, imaging, and safety in a well-compensated NASH cirrhotic cohort treated with resmetirom, a thyroid hormone receptor-beta ive agonist, for 52 weeks	Stephen Harrison	Received

P01-001	Single-nucleotide polymorphisms in the DNA repair genes affect the risk of nonalcoholic fatty liver disease occurrence	Sylwia Ziólkowska	Received

P02-001	Non-alcoholic fatty liver disease and sarcopenic obesity	Kateryna Pivtorak	Received

P06-001	High yield of systematic hepatitis B virus screening among migrants in Amsterdam, the Netherlands with increased risk for non-alcoholic fatty liver disease	Anne-Marieke Van Dijk	Received

P01-002	Pulse wave velocity is correlated with decline in renal filtration rate in non-alcoholic fatty liver disease patients	Said TAHARBOUCHT	Received

P06-002	Pancreatic T1 values on magnetic resonance imaging are correlated with portal inflammation scores on liver biopsy in patients with non-alcoholic fatty liver disease	Anne Linde Mak	Received

P05-002	Impact of bariatric surgery, gender, vitality and depressive symptoms on self-perceived health of obese patients with non-alcoholic fatty liver disease	Jesús Funuyet-Salas	Received

P02-002	Simple anthropometrics may improve non-invasive tests for the prediction of fibrosis in an elderly population: the Rotterdam study	Laurens van Kleef	Received

P03-002	Utility of FIB-4 thresholds to identify patients with at-risk F2-F3 nonalcoholic steatohepatitis based on screening data from a 2000 patient biopsy-confirmed cohort of resmetirom phase 3 trial (MAESTRO-NASH)	Jrn Schattenberg	Received

P07-002	Metabolic syndrome correlates to a higher risk of fibrosis by surrogate scores compared to patients who do not fully meet the syndrome diagnostic criteria	Valentino Osti	Received

P04-002	Multi-omic machine learning panel accurately stage fibrosis in asian patients with NAFLD: a prospective derivation and validation study	Jin Chai	Received

P07-003	The effects of a structured dietetic intervention in patients with NAFLD	Dominic Crocombe	Received

P01-003	Sodium-glucose cotransporter 2 inhibitor versus sulfonylurea in patients with type 2 diabetes and nonalcoholic fatty liver disease	Yumie TAKESHITA	Received

P04-003	Effects of coping, quality of life and liver fibrosis on self-efficacy of patients with non-alcoholic fatty liver disease	Jesús Funuyet-Salas	Received

P02-003	Prediction of fibrosis progression and clinical outcomes with non-invasive tests in 10 years follow up of patients with nonalcoholic steatohepatitis	Claudia Oliveira	Received

P05-003	Advanced fibrosis in nonalcoholic fatty liver disease is independently associated with reduced renal function	Gres Karim	Received

P06-003	A co-micronized formulation of palmitoylethanolamide and phenolic compounds from olive leaves lessens hepatic dysmetabolic state in high-fat diet-induced obese mice	Stefania Melini	Received

P03-003	Fully connected neural network-based serum surface-enhanced Raman spectroscopy accurately identify nonalcoholic steatohepatitis	Feng Gao	Received

P04-004	Intercellular adhesion molecule-1 is involved in western diet-induced liver damage and metabolic regulation in mice	Laura Gebert	Received

P02-004	The HDL proteome serves as a mirror for liver dysmetabolism and can delineate healthy from unhealthy obesity	Fiona McGillicuddy	Received

P01-004	Effects of high fat diet on development of NASH in the NIF mouse model	Sofia Mayans	Received

P06-004	Insulin resistance in obese children with non-alcoholic fatty liver fibrosis	Natalia Zavhorodnia	Received

P07-004	NASH PASS: a registry to inform study design and accelerate patient enrollment	Alejandra Macias Pulido	Received

P03-004	Estrogen-related receptor alpha regulates ribosomal stalk protein RPLP1-dependent translation of lysosome and autophagy proteins in fasting and non-alcoholic steatohepatitis (NASH).	Brijesh Kumar Singh	Received

P05-004	Exploring the impact of the genetic PNPLA3 I148M variant on primary human hepatic stellate cells by using healthy and diseased 3D extracellular matrix scaffolds	Elisabetta Caon	Received

P04-005	Carvedilol modifies metabolomics of bile acids in mice: effect of nonalcoholic steatohepatitis	Stanislav Micuda	Received

P01-005	Hydroxysteroid 17-beta sterol dehydrogenase 13 knockdown improves liver steatosis in mice fed a high-fed diet	Shehroz Mahmood	Received

P06-005	Prospective relationship between PCOS plus NAFLD at age 17 years, and insulin resistance and atherogenic dyslipidaemia 10 years later in a longitudinal cohort study	Oyekoya Ayonrinde	Received

P02-005	Characterization of cognitive function in patients with non-alcoholic fatty liver disease and association with the risk of progressive non-alcoholic steatohepatitis	Aurora Nicolosi	Received

P03-005	Burden of hepatocellular cancer in patients with type-2 diabetes mellitus: a 2010-2020 national cohort study	Juan Pablo Scarano Pereira	Received

P05-005	Community NAFLD screening programme in patients with T2DM indicates high burden of undiagnosed liver disease	Emma McCormick	Received

P03-006	Echocardiography-based markers of subclinical cardiac dysfunction in individuals with non-alcoholic fatty liver disease and preserved ejection fraction	Angelo Armandi	Received

P01-006	Contribution of multiple hit to NAFLD pathology differ in obese and non obese population	Souveek Mitra	Received

P05-006	Prevalence and clinical characteristics of nonalcoholic fatty liver disease in morbidly obese patients before and after bariatric surgery	Sangmi Jang	Received

P04-006	Dysregulation of the urea cycle enzymes determines a more severe NAFLD phenotype in diamond mice	Rocío Gallego-Durán	Received

P07-006	miR-423-5p is associated with hepatic injury in a non-alcoholic fatty liver disease (NAFLD) preclinical model	Rocío Montero	Received

P02-006	Hepatoprotective effects of semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC progression	Andreas Nygaard Madsen	Received

P06-006	Presumed NASH fibrosis as per noninvasive screening blood marker LIVERFASt-GP is predictive for Covid-19 short-term severe outcome	Mona munteanu	Received

P06-007	Novel MAFLD classification: a more realistic concept of fatty liver disease	Juliana Serrazina	Received

P04-007	Impact of genes related to metabolic MAFLD in response to hypocaloric dietary intervention: nutrigenomic analysis	Sheila Gato Zambrano	Received

P01-007	Association between advanced stage of liver fibrosis in patients with metabolic fatty liver disease and intestinal permeability	Tatyana Krolevets	Received

P07-007	A specific lipidomic fingerprint is associated with the development of nalfd-associated hcc in an animal model	Jian Huang	Received

P02-007	Impact of dietary intake on the risk for significant fibrosis in patients with MAFLD	Nuria Pérez Diaz del Campo	Received

P05-007	Target metabolomics reveals the inhibition of the bile acid alternative pathway promotes the development of non-alcoholic steatohepatitis in mice	Dapeng Li	Received

P03-008	Pregnancy as a unique opportunity to identify NAFLD in women: a prospective assessment	Tatyana Kushner	Received

P01-008	LIVRQNac increases fatty acid oxidation in a primary human hepatocyte model of non-alcoholic steatohepatitis	Matthew Russell	Received

P07-008	Quantification of hepatic steatosis with a novel attenuation imaging ultrasound technique (QAI): preliminary findings on reproducibility and diagnostic accuracy	Mattia Paratore	Received

P04-008	Functionalizing novel cancer related genes in liver disease and liver regeneration	Nooshin Nourbakhsh	Received

P05-008	Immune modulation by RIPK3 in NAFLD progression towards hepatocellular carcinoma	André F. L. Cardador	Received

P06-008	Utilization of gluconeogenic glucose-6-phosphate via pentose phosphate pathway is increased in mice fed a high fat/high sugar diet compared to a high sugar diet alone	Getachew Debas Belew	Received

P02-008	Therapeutic target identification by genome-wide RNAi screening in non-alcoholic fatty liver (NAFLD)	Amanpreet Kaur	Received

P06-009	A monoclonal antibody targeting non-junctional Claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity	Antonio Saviano	Received

P07-009	Role of TGR5 in fat-to-liver communication through extracellular vesicles in the context of NAFLD	André L. Simão	Received

P04-009	Lipid profiling of extracellular vesicles and plasma in people with non-alcoholic fatty liver disease	Dan Wang	Received

P05-009	Fluorescent advanced glycation end products levels in the brazilian longitudinal study of adult health (ELSA-Brasil): a potential biomarker for risk stratification of non-alcoholic fatty liver disease-associated steatosis	Evelyn Pereira	Received

P01-009	Predictors of steatohepatitis in hypertensive nonalcoholic fatty liver disease patients	Iryna Tverezovska	Received

P02-009	Identifying novel epigenetic regulators of non-alcoholic fatty liver disease using in vivo RNAi screen	Chee Chong Jonathan Lek	Received

P03-009	Oxygen-nutrient mismatch correction by obeticholic acid suggests mechanism of action in NASH	Gerond Lake-Bakaar	Received

P01-010	Relationship between endothelial dysfunction and non-alcoholic fatty liver disease	Kateryna Pivtorak	Received

P04-010	Non-invasive tests for non-alcoholic fatty liver disease (NAFLD) in a multi-ethnic population. The Helius study	Anne-Marieke Van Dijk	Received

P06-010	A translational rat model to study metabolic associated fatty liver disease with fibrosis and portal hypertension	Juan Manuel Pericàs	Received

P02-010	Interactive role of non-invasive assessment of insulin resistence and liver fibrosis in the prediction of cardiovascular events in patients with MAFLD	Diego Martinez-Urbistondo	Received

P05-010	Multiparametric ultrasound evaluation of the liver: whom would mostly benefit?	Iulia Minciuna	Received

P07-010	Double-blinded randomized controlled trial assessing the effect of consecutive fecal microbiota transplantation (FMT) on hepatic steatosis in patients with non-alcoholic fatty liver disease (NAFLD)	Koen van Son	Received

P04-011	Improving diagnostic performance of liver fibrosis, NASH and NAFLD activity score (NAS) with 3D vector magnetic resonance elastography (MRE)	Nana Owusu	Received

P02-011	Yeast -glucan improves insulin sensitivity and hepatic lipid metabolism in mice humanized with obese type 2 diabetic gut microbiota	Kathleen Mitchelson	Received

P07-011	Telmisartan improves hepatic mitochondrial energy metabolism in mouse nutritional model of nonalcoholic steatohepatitis	Pavla Stankova	Received

P03-011	NAFLD-related liver fibrosis is associated with impaired bone mineralization and degraded micro-architecture in obesity	Ilaria Barchetta	Received

P06-011	Glutaminolysis and steatosis to steatohepatitis transition: role of glutaminase	Rocío Gallego-Durán	Received

P05-011	A global survey of health care professionals awareness of nonalcoholic fatty liver disease	Stan Driessen	Received

P01-011	Liver stiffness is associated with excess mortality in the general population driven by heart failure: The Rotterdam study	Laurens Van Kleef	Received

P02-012	Impact of renaming NAFLD to MAFLD in a single italian center	Valentina Cossiga	Received

P03-012	Diagnosis of NAFLD with and without fibrosis using a lower ALT reference range in the iLFT system	Christopher Byrne	Received

P01-012	The role of Gremlin-1 in pathogenesis and treatment in rodent and human NASH	Paul Horn	Received

P07-012	Predictors of liver stiffness changes in a consecutive cohort of patients with NAFLD and longitudinal follow up	Mirko Zoncapè	Received

P06-012	The use of spleen stiffness measurement as non-invasive tool to identify histological cirrhosis in individuals with non-alcoholic fatty liver disease	Angelo Armandi	Received

P05-012	Quantitification of hepatic steatosis in patient with non-alcoholic fatty liver disease : comparison of sound speed, attenuation coefficient and continuous CAP measurements with MR-PDFF	Rémi COLLIN	Received

P04-012	Pegozafermin improved liver histology, liver-related non-invasive tests (NITS) and metabolic profiles in an open-label cohort of a phase 1b/2a study in subjects with non-alcoholic steatohepatitis	Cindy Hartsfield	Received

P04-013	NAFLD is associated with significantly higher risk of cardiovascular outcomes in the absence of fibrosis - a prospective UK Biobank analysis in 33,616 individuals	Anneli Andersson	Received

P03-013	The SEMA7A_R148W mutation promotes lipid accumulation and NAFLD progression by increasing its localization on hepatocyte surface	Jin Chai	Received

P01-013	Clinical translatability of the GAN diet-induced obese and biopsy-confirmed mouse model of NASH	Susanne Pors	Received

P06-013	Free light chains: a new potential biomarker for disease stratification in non-alcoholic steatohepatitis	Francesca DAmbrosio	Received

P07-013	Circulating Interleukin-32 levels are associated with arterial hypertension in individuals at risk of NAFLD	Melissa Tomasi	Received

P02-013	Prevalence and risk factors for non-alcoholic fatty liver disease in patients with polycystic ovary syndrome: a systematic review, meta-analysis, and meta-regression	Clara Sabiote Cartes	Received

P05-013	Clinical variables influence performance of non-invasive tests for non-alcoholic fatty liver disease	Anne-Marieke Van Dijk	Received

P03-014	Branched-chain amino acid catabolism and hepatic stellate cell activation	Rory Turner	Received

P05-014	Modelling clinical effect of patatin-like phospholipase domain containing 3 mutation in hepatocytes on severity of disease progression in 3D human NASH model	Thomas Hofstetter	Received

P06-014	Micro-lAIver: artificial intelligence-powered drug screening platform for 3D-bioprinted human liver microspheres	Francesco De Chiara	Received

P02-014	Non-alcoholic fatty liver disease related knowledge among egyptians: an exploratory cross-sectional study	Mona Hegazy	Received

P04-014	Decreases in liver cT1 accurately reflect therapy-induced histological improvements in NASH: a multi-centre pooled analysis	Cayden Beyer	Received

P01-014	Sex-specific hepatoprotective effects of long-term semaglutide treatment in GAN diet-induced obese and biopsy-confirmed mouse model of NASH	Kristoffer Voldum-Clausen	Received

P07-014	Phosphatidylcholines (36:1) and (36:3) are increased in postmenopausal women with NAFLD.	Dan Wang	Received

P07-015	Multiparametric liver ultrasound assessment for stratification of non-alcoholic fatty liver disease (NAFLD) severity: a possible role for viscosity	Antonio Liguori	Received

P04-015	MRI assessment (cT1) with LiverMultiScan following VCTE improves the diagnostic yield for high-risk NASH	Cayden Beyer	Received

P05-015	Single-nucleus ATAC-seq elucidates major modules of gene regulation in the development of non-alcoholic fatty liver disease	Fumihiko Takeuchi	Received

P01-015	Meat consumption and PNPLA3 polymorphism are associated with fatty liver in a multi-center cross-sectional study	Claudia Oliveira	Received

P02-015	Impact of sexual dimorphism and aging on NAFLD severity and advanced fibrosis	Mona Hegazy	Received

P03-016	Secretome analysis of non-diabetic patients with non-alcoholic fatty liver disease identifies glucose-dependent insulinotropic peptide (GIP) and interferon gamma-induced protein 10 (IP-10) as biomarkers of at risk non-alcoholic steatohepatitis	Gian Paolo Caviglia	Received

P05-016	Association of thyroid dysfunction and raised sgpt values in children with obesity and severe obesity in greece: results of a tertiary paediatric hospital experience	Anastasia Konidari	Received

P04-016	Prevalence of subclinical cardiovascular disease in patients with non-alcoholic fatty liver disease. Analysis of the Paracelsus 10.000 cohort study	Florian Koutny	Received

P07-016	Calorie restriction combined with metformin promote the remission of NAFLD	Elisabet Rodríguez-Tomàs	Received

P01-016	Primary data analyses of MAESTRO-NAFLD-1: a 52-week randomized double-blind placebo-controlled Phase 3 trial of resmetirom in patients with nonalcoholic fatty liver disease	Stephen Harrison	Received

P06-016	The controlled attenuation parameter has limited value in assessing the degree of steatosis in different stages of compensated chronic liver disease	Madalina Gabriela Taru	Received

P02-016	Metabolic associated fatty liver disease: association between the three different criteria definition and hepatic and cardiovascular disease	Rosa Lombardi	Received

P02-017	Type 2 diabetes and religious fasting: effects on metabolism and liver steatosis	Paul Manka	Received

P05-017	3D human NASH model as a screening-based discovery approach for ing and prioritizing drug candidates	Simon Strbel	Received

P07-017	NAFLD identification gap in italian primary care is due to a lack of proper ICD9 coding for disease	Marianxhela Dajko	Received

P06-017	Cost-effectiveness of magnetic resonance elastography for non-alcoholic steatohepatitis fibrosis in the United Kingdom	Michael Kalutkiewicz	Received

P01-017	Non alcoholic fatty liver disease is associated to post-acute COVID syndrome	Fabrizio Mancuso	Received

P04-017	Effect of smartphone-assisted lifestyle modification intervention in MAFLD patients: a randomized controlled trial	Suraphon Assawasuwannakit	Received

P03-017	A calorie-unrestricted low carbohydrate high fat diet improves nonalcoholic fatty liver disease (NAFLD) activity score (NAS) and HbA1c in type 2 diabetes: a six-month randomised controlled trial	Camilla Dalby Hansen	Received

P02-018	The paraoxonase gene family in the etiology and progression of obesity and associated liver disease: a genetic case-control study	Evelien Van Dijck	Received

P03-018	Prognostic value of liver stiffness and FIB-4 score in individuals with cirrhosis due to non-alcoholic fatty liver disease without previous liver decompensation	Amina Abdulle	Received

P05-018	Multiplex immunostaining identifies novel immune cell markers for non-alcoholic fatty liver disease and primary sclerosing cholangitis	Marlene Kohlhepp	Received

P04-018	Proteomics and spatial transcriptomics show that ADAMTSL2 is a promising biomarker in NAFLD with significant fibrosis	Elisabeth Galsgaard	Received

P07-018	Liraglutide ameliorates steatotic changes in a cell culture model of tamoxifen-induced steatosis by downregulation of lipogenic ACSL1 and SREBP-1c signaling pathways	Tea Omanovic Kolaric	Received

P06-018	foz/foz mice with non-alcoholic steatohepatitis feature pathological cardiac hypertrophy	Sebastian Bott	Received

P01-018	Clinical characteristics of non-alcoholic fatty liver disease in pregnant women with varying degrees of obesity	Lina Bahniy	Received

P02-019	Missed opportunities to co-diagnose alcohol-related liver disease in patients diagnosed with non-alcoholic fatty liver disease	Tobias Maharaj	Received

P07-019	Aging contributes to the loss of glycerophospholid in adipocytes in NAFLD mice model	Gerard Baiges	Received

P05-019	Tackling stages of fibrosis in metabolic-associated liver diseases with transcriptome profiles	Eva Kocar	Received

P01-019	Validation of elastography criteria and cACLD risk model for diagnosis of compensated advanced Chronic liver disease (cACLD) in a UK cohort of NAFLD patients	Antonio Liguori	Received

P04-019	Long term safety and efficacy of saroglitazar in NAFLD/NASH population: a prospective, single arm, real world study	Sujit Chaudhuri	Received

P03-019	Impact of intermittent fasting on anthropometric and clinical outcomes in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis	Marcia Lange	Received

P04-020	Dysregulated wound healing contributes to the progression of post-transplant non-alcoholic steatohepatitis	Khairunnadiya (Nadia) Prayitno	Received

P02-020	NAFLD and liver stiffness predict clinical events and chronic kidney disease in patients with type-2 diabetes	Jesús Rivera	Received

P07-020	Fatty liver disease in ALPHA-1 deficiency patients	Hassaan Yousuf	Received

P03-020	Hepatocellular cancer surveillance in cirrhotic patients with fatty liver disease	Chloe Attree	Received

P01-020	Antagonizing sodium taurocholate co-transporting polypeptide (NTCP) on NK cells from NALFD patients elevate their activity and mediate activated hepatic stellate cells killing	Ahmed Salhab	Received

P05-020	Performance of FIB-4 compared to vibration controlled transient elastography in people with type 1 and type 2 diabetes	Jonathan Mertens	Received

P06-020	Predictive survival-time modelling of non-alcoholic steatohepatitis (NASH) fast progressors using real-world evidence	Nils Svangrd	Received

P07-021	Molecular mechanisms involved in metabolic dysfunction- associated fatty liver disease in cholecystectomized patients	Nahum Méndez-Sánchez	Received

P01-021	Tissue resident NK NTCP- transplanted to immunosuppressed mice exhibiting liver fibrosis and fed with high fat diet (HFD) alleviate intestinal fibrosis and lipid profile	Johnny Amer	Received

P06-021	Comparison of severity of liver damage, metabolic alterations and cardiovascular damage in patients with NAFLD attending the hepatology clinic over the last three decades	Rosa Lombardi	Received

P03-021	Beta 7 integrin-mediated intestinal migration of pro-inflammatory monocytes contributes to western-style diet-induced obesity and non-alcoholic fatty liver disease in mice	Sreepradha Eswaran	Received

P04-021	Expression dynamics of genes involved in lipid, glucose and xenobiotic metabolism after exposure to nuclear receptor ligands in 3D primary human hepatocyte spheroids	Petr Pavek	Received

P05-021	Fatty hepatocytes induce skeletal muscle atrophy in vitro: a new three-dimensional platform to study the protective effect of albumin in non-alcoholic fatty liver disease	Ainhoa Ferret Miñana	Received

P02-021	Investigation of the plasma proteome to identify drug targets for non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease	Jun Liu	Received

P06-022	The impact of metabolic comorbidities and alcohol consumption on FIB-4 and NFS performance in MAFLD: a multicentric preliminary data	Annalisa Cespiati	Received

P07-022	Promising ultrasound tools in the management of patients with NAFLD	Isabel Garrido	Received

P01-022	MRI in NAFLD: calculation of liver fat mass and investigation of its correlation with liver volume and steatosis grade	PANAGIOTIS KOUSSIS	Received

P05-022	Sex-related differences of hepatic lipid metabolism and mitochondrial function in epileptic WAG/Rij rats: effect of early lipopolysaccharide challenge	Claudio Pirozzi	Received

P03-022	Comparison of metabolic alterations, hepatic and cardiovascular damage between HIV patients with steatosis and primary NAFLD: role of visceral adiposity	Felice Cinque	Received

P04-022	Administrative coding for non-alcoholic fatty liver disease is accurate in swedish patients	Hanne strm	Received

P02-022	Prevalence and risk factors of NAFLD fibrosis amongst penitentiary population in Catalonia. Preliminary results from the PRISONAFLD study.	Laura Cecconi	Received

P01-023	The crosstalk of liver, muscle and adipose tissue transcriptomics upon exercise in patients with non-alcoholic fatty liver disease	Veera Houttu	Received

P07-023	Development of fatty liver disease in the portuguese population: can we predict it?	Juliana Serrazina	Received

P06-023	Prevalence of non-alcoholic fatty liver disease (NAFLD) in middle-aged men and women with overweight and normal liver enzymes, and diagnostic accuracy of non-invasive proxies	Koen Van Son	Received

P05-023	Anaerobutyricum soehngenii as a next generation therapeutic microbe in a mouse model of non-alcoholic fatty liver disease	Anne Linde Mak	Received

P03-023	Obeticholic acid modulates DDAH-ADMA-eNOS axis and attenuates portal pressure in an experimental non-alcoholic fatty liver disease	Balasubramaniyan Vairappan	Received

P04-023	Growth and development of infants born to mothers with nonalcoholic fatty liver disease in pregnancy: a longitudinal study	Aliza Gross	Received

P02-023	Comparison of survival rates as predicted by total tumor volume or tumor burden score in patients with hepatocellular carcinoma concurrent with fatty liver disease	Jian-Hong Zhong	Received

P07-024	Performance of fatty liver index in the prediction of advanced chronic liver disease in nonalcoholic fatty liver disease	Nouha Trad	Received

P03-024	Steroidomic profile is associated with adipose tissue insulin resistance and severe liver fibrosis in non-diabetic patients with non-alcoholic fatty liver disease	Chiara Rosso	Received

P05-024	VEGF and TGF-1 in children with non-alcoholic fatty liver fibrosis	Natalia Zavhorodnia	Received

P06-024	Anti-pd-1 treatment affects lipidomic profile in an animal model of NAFLD-HCC	Jian Huang	Received

P04-024	The prevalence and the assessment of significant and advanced fibrosis of the liver by non-invasive tests in patients with type 2 diabetes mellitus	Marie Coessens	Received

P02-024	Boosting drug development in NASH through integrated research platforms: proposal of a master protocol for a NASH platform trial	Juan Manuel Pericàs	Received

P04-025	A screening strategy of non-alcoholic fatty liver disease in endocrine outpatients using the fibrosis-4 score.	María Sanz de Pedro	Received

P01-025	Effect of peroxisome proliferator-activated receptor-alpha/gamma agonism on fibrosis-4 index in type 2 diabetes mellitus patients with elevated cardiovascular risk profile by sex, age, regional and ethnical differences	Vivian de Jong	Received

P06-025	Patients with compensated cirrhosis due to NASH show decreased plasma levels of sphingolipids and MCP-1 and increased leptin	Antonio Liguori	Received

P05-025	Urinary lithogenic profile in patients with non-alcoholic fatty liver disease (NAFLD)	Antonio Liguori	Received

P02-025	A higher fibrosis-4 (FIB-4) score is associated with higher healthcare costs and hospitalizations in patients with nonalcoholic steatohepatitis	Stephen Dodge	Received

P07-025	Hepatic senescence is associated with clinical progression of NAFLD/NASH: role of BMP4 and its antagonist Gremlin1	Ritesh Kumar Baboota	Received

P03-025	Late chronotype is associated with significant liver fibrosis in patients with non-alcoholic fatty liver disease	Gabriele Castelnuovo	Received

About us

FAQs

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 15/09/2022 TO 15/09/2023

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access